Unicycive Therapeutics (UNCY) Non-Current Assets (2021 - 2026)
Unicycive Therapeutics' (UNCY) quarterly Non-Current Assets came in at $861000.0 in Q1 2026, up 43.26% YoY from $601000.0 in Q1 2025, and up 394.83% on a QoQ basis from $174000.0 in Q4 2025.
Unicycive Therapeutics (UNCY) Non-Current Assets (2021 - 2026) Analysis & Trends
Unicycive Therapeutics (UNCY) has 6 years of Non-Current Assets data on file, last reported at $861000.0 in Q1 2026.
- Quarterly Non-Current Assets rose 43.26% year-over-year to $861000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.8 million (down 34.74% YoY) and the FY2025 annual result came in at $174000.0, down 75.83% from the prior year.
- Non-Current Assets rose to $861000.0 in Q1 2026, from $174000.0 in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $1.0 million in Q1 2023 to a low of $174000.0 in Q4 2022.
- A 5-year average of $583235.3 and a median of $647000.0 in 2024 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2023 — Non-Current Assets surged 355.17% — and 2025, when it sank 75.83%.
- Tracing UNCY's Non-Current Assets over 5 years: stood at $174000.0 in 2022, then surged by 355.17% to $792000.0 in 2023, then dropped by 9.09% to $720000.0 in 2024, then slumped by 75.83% to $174000.0 in 2025, then jumped by 394.83% to $861000.0 in 2026.
- The last three Non-Current Assets figures came in at $861000.0 (Q1 2026), $174000.0 (Q4 2025), and $324000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | Unicycive Therapeutics | 151.01 Mn | 151.01 Mn | - | 709,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 709,000.00 |
| Mar 31, 2026 | 861,000.00 |
| Dec 31, 2025 | 174,000.00 |
| Sep 30, 2025 | 324,000.00 |
| Jun 30, 2025 | 469,000.00 |
| Mar 31, 2025 | 601,000.00 |
| Dec 31, 2024 | 720,000.00 |
| Sep 30, 2024 | 833,000.00 |
| Jun 30, 2024 | 647,000.00 |
| Mar 31, 2024 | 709,000.00 |
| Dec 31, 2023 | 792,000.00 |
| Sep 30, 2023 | 873,000.00 |
| Jun 30, 2023 | 953,000.00 |
| Mar 31, 2023 | 1.02 Mn |
| Dec 31, 2022 | 174,000.00 |
| Sep 30, 2022 | 215,000.00 |
| Jun 30, 2022 | 256,000.00 |
| Mar 31, 2022 | 296,000.00 |
| Dec 31, 2021 | 333,000.00 |